CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Q4 2024 Earnings Call Transcript February 11, 2025 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.48 EPS, ...

Citi raised the firm’s price target on Exelixis (EXEL) to $45 from $38 and keeps a Buy rating on the shares following the Q4 report. The ...

Harry Wilson returns with his advice for all seven races at Newbury on Saturday – and the three live on ITV4 from Warwick . .

The company is advancing its oncology pipeline with significant progress in cabozantinib and zanzalintinib, aiming for ...

Exelixis has made significant strides in establishing itself as a multi-compound, multi-franchise oncology business.

Djelo (FR) 5-4fav (11-10) Handy on outer, raced in 4th after 3rd, closed up after 7th, tracked leader 11th, outpaced by winner before 3 out, soon well beaten and plugged on same pace, 2nd of 6 ...

Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock. Exelixis ( NASDAQ:EXEL ) Full Year 2024 Results Key ...